ArticleFrontiers in oncology2024

Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression.

Meiling Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.